Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease

Gut
D W HommesTillman Pearce

Abstract

Interferon gamma is a potent proinflammatory cytokine implicated in the inflammation of Crohn's disease (CD). We evaluated the safety and efficacy of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe CD. A total of 133 patients with Crohn's disease activity index (CDAI) scores between 250 and 450, inclusive, were randomised to receive placebo or fontolizumab 4 or 10 mg/kg. Forty two patients received one dose and 91 patients received two doses on days 0 and 28. Investigators and patients were unaware of assignment. Study end points were safety, clinical response (decrease in CDAI of 100 points or more), and remission (CDAI < or =150). There was no statistically significant difference in the primary end point of the study (clinical response) between the fontolizumab and placebo groups after a single dose at day 28. However, patients receiving two doses of fontolizumab demonstrated doubling in response rate at day 56 compared with placebo: 32% (9/28) versus 69% (22/32, p = 0.02) and 67% (21/31, p = 0.03) for the placebo, and 4 and 10 mg/kg fontolizumab groups, respectively. Stratification according to elevated baseline C reactive protein levels resulted in a decreased placebo response a...Continue Reading

Citations

Jan 6, 2010·EMBO Molecular Medicine·Jana Pachlopnik SchmidGeneviève de Saint Basile
Jun 19, 2013·Autoimmunity Reviews·Giovanni MonteleoneFrancesco Pallone
Sep 10, 2013·Experimental Eye Research·Stephen C PflugfelderCintia S de Paiva
Sep 17, 2013·Trends in Immunology·Paolo BiancheriThomas T MacDonald
Jul 30, 2008·The Journal of Experimental Medicine·Uwe NiesnerAndreas Radbruch
Sep 4, 2013·The Journal of Experimental Medicine·Mario KreutzfeldtDoron Merkler
Feb 7, 2009·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Cécile BeaurepaireDerek M McKay
May 20, 2009·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Rivkah GonskyStephan R Targan
Jan 9, 2009·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Michel A BoivinThomas Y Ma
Sep 12, 2007·Journal of Gastroenterology and Hepatology·Peter M Irving, Peter R Gibson
Jan 16, 2007·Annual Review of Medicine·Theresa T Pizarro, Fabio Cominelli
Aug 23, 2008·Annual Review of Pathology·Richard N Mitchell
Nov 10, 2009·Digestive Diseases·Richard S Blumberg
Mar 3, 2007·The Journal of Clinical Investigation·Warren StroberPeter Mannon
Nov 16, 2011·BMC Medicine·Ivan MonteleoneGiovanni Monteleone
Jul 4, 2008·Pharmacogenomics·Helga-Paula TörökAstrid Konrad
Jan 18, 2008·World Journal of Gastroenterology : WJG·Patricia L Kozuch, Stephen B Hanauer
Jan 18, 2008·World Journal of Gastroenterology : WJG·David Q Shih, Stephan R Targan
Jul 31, 2008·World Journal of Gastroenterology : WJG·Fausto Sanchez-MunozJesus-K Yamamoto-Furusho
Sep 25, 2009·World Journal of Gastroenterology : WJG·Jeff Huaqing Ye, Vazhaikkurichi M Rajendran
Feb 26, 2011·World Journal of Gastroenterology : WJG·Guillaume BouguenLaurent Peyrin-Biroulet
Feb 14, 2014·Science Translational Medicine·Mehdi RashighiJohn E Harris
Oct 13, 2011·Expert Opinion on Pharmacotherapy·Mario CottoneFilippo Mocciaro
Oct 1, 2007·Expert Review of Gastroenterology & Hepatology·Timothy L Zisman, Sunanda V Kane
Aug 14, 2015·International Journal of Molecular Sciences·Boel De Paepe, Jana Zschüntzsch
Jul 3, 2010·Expert Review of Clinical Immunology·Arik DahanEllen M Zimmermann
Sep 1, 2007·Expert Review of Clinical Immunology·Trevor A WinterStefan Schreiber
Jul 1, 2009·Expert Review of Clinical Pharmacology·Alfredo PapaAntonio Gasbarrini
Aug 21, 2007·Expert Opinion on Biological Therapy·C Janneke van der Woude, Daniel W Hommes
Sep 15, 2010·Expert Opinion on Investigational Drugs·Mario CottoneSara Renna
Jul 14, 2009·Expert Opinion on Biological Therapy·Gerald W Dryden
Apr 21, 2010·Expert Opinion on Emerging Drugs·Ulrike Strauch, Jürgen Schölmerich
Sep 18, 2013·International Reviews of Immunology·Edoardo TronconeGiovanni Monteleone
Jul 2, 2011·Expert Opinion on Pharmacotherapy·Suzanne C DonnellyPaul J Ciclitira
Apr 16, 2008·Expert Opinion on Therapeutic Targets·Arthur Kaser, Herbert Tilg
Jul 4, 2012·Oncoimmunology·Erika VacchelliGuido Kroemer
Sep 24, 2013·JAK-STAT·Isabella RauchThomas Decker
Nov 12, 2014·Frontiers in Pharmacology·Sabine RingkowskiCristan Herbert
Sep 23, 2014·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Rajkumar CheluvappaMichael C Grimm
May 15, 2007·Lancet·Daniel C Baumgart, William J Sandborn
May 1, 2008·Clinica Chimica Acta; International Journal of Clinical Chemistry·Aldona T PietrzakJacek M Roliński
Mar 11, 2018·Scandinavian Journal of Gastroenterology·Bani AhluwaliaLena Öhman
Oct 14, 2011·Inflammatory Bowel Diseases·J VerdierF M Ruemmele
Apr 18, 2012·Inflammatory Bowel Diseases·Thomas T MacDonaldGiovanni Monteleone

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.